Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
FDA Expands Approval of Pembrolizumab for First-Line Treatment of Non-Small Cell Lung CancerFDA approved the immune checkpoint inhibitor pembrolizumab to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.
-
HPV Vaccination Linked to Decreased Oral HPV InfectionsA study of more than 2,600 young adults found that the prevalence of oral infection with four HPV types, including two cancer-causing types, was 88% lower in those who reported receiving at least one dose of an HPV vaccine than in those not vaccinated.
-
Midostaurin Approved by FDA for Acute Myeloid LeukemiaThe FDA has approved midostaurin for patients with newly diagnosed acute myeloid leukemia (AML) with mutations in the FLT3 gene. The approval also covers several rare conditions.
-
Study Identifies Genetic Mutations in Tumors From 10,000 Patients with Metastatic CancerResearchers at Memorial Sloan Kettering Cancer Center have reported the results of an initiative to characterize the genetic mutations in tumors from more than 10,000 patients with advanced cancer treated at the center.
-
New on NCI’s Websites for May 2017NCI periodically provides updates on new websites and other online content of interest to the cancer community.
-
FDA Approves Immunotherapy Drugs for Patients with Bladder CancerThe FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors.
-
Intensive Pre-Stem Cell Transplant Regimen May be Best for Younger Patients with AML, MDSResults from a large phase III clinical trial suggest that a highly intensive preparatory regimen should be used for younger patients with acute myeloid leukemia or myelodysplastic syndromes preparing to undergo an allogeneic stem cell transplant.
-
Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a DecadeFDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer.
-
FDA Grants Brigatinib Accelerated Approval for Metastatic Non-Small Cell Lung CancerOn April 28, the FDA granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy.
-
Counseling Improves Survivorship Plan Implementation for Low-Income Breast Cancer SurvivorsIn a randomized trial, low-income women who role-played talking with their doctor about their survivorship care plan in a counseling session reported receiving more of their recommended care than women who did not get counseling.
-
NCI ALMANAC: A New Tool for Research on Cancer Drug CombinationsNCI has released a new, easy-to-use resource called the NCI ALMANAC to help researchers identify potentially promising combinations of cancer drugs.
-
Collection of Patient-Reported Outcomes Feasible in Cancer Clinical TrialsCancer patients, even those who are undergoing difficult treatments, are willing to devote time to completing thorough assessments of the side effects they encounter in clinical trials, a new study finds.
-
Nanoparticles Create Effective CAR T Cells in Living MiceResearchers have developed a method to genetically engineer cancer-fighting immune cells in living animals using nanoparticles that carry DNA. The new study shows that the resulting immune cells, known as CAR T cells, eliminated leukemia in mice.
-
Patients Who Choose No Intervention for Small Thyroid Cancers Report Lack of SupportPatients who choose not to pursue immediate biopsy or treatment for small, asymptomatic thyroid cancers, or suspected cancers, can experience a lack of support from doctors and loved ones, a new study shows.
-
PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH MutationsStudies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.
-
Making Greater Progress Against Cancer—Not Just a Hope but a RealityActing NCI Director Dr. Doug Lowy discusses what he calls encouraging news in the most recent Annual Report to the Nation and how NCI is helping to achieve further progress against cancer.
-
FDA Approves Pembrolizumab for Hodgkin LymphomaThe FDA approved pembrolizumab for the treatment of some adult and pediatric patients with classical Hodgkin lymphoma.
-
Studies Identify Potential Treatment Strategies for Pediatric DIPG Brain TumorsTwo studies have identified proteins that drive growth of diffuse intrinsic pontine glioma (DIPG) tumor cells. Blocking these targets with investigational drugs slowed tumor growth in animal models.
-
FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian CancerThe FDA approved the PARP inhibitor niraparib for use as a maintenance therapy for some women with advanced ovarian cancer.
-
FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast CancerThe FDA has approved a new targeted therapy, ribociclib, and expanded its earlier approval of another targeted therapy, palbociclib, for some women with metastatic breast cancer.